Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXLA Axcella Health	$0.40	$0.84	$0.34 ▼ $41.25	$1.18M	0.46	267,009 shs	6,782 shs
CDTX Cidara Therapeutics	$49.55 -2.6%	$30.03	$10.14 ▼ $56.83	$1.00B	1.14	194,692 shs	212,918 shs
ERYP ERYTECH Pharma	$3.10	$4.66	$0.30 ▼ $1.47	$105.77M	2.69	93,510 shs	N/A
FENC Adherex Technologies	$8.85 -2.2%	$7.78	$3.96 ▼ $9.29	$244.12M	0.39	92,676 shs	77,960 shs
XFOR X4 Pharmaceuticals	$1.49 -5.1%	$2.89	$1.46 ▼ $26.96	$8.63M	0.54	141,316 shs	286,590 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXLA Axcella Health	0.00%	0.00%	0.00%	0.00%	0.00%
CDTX Cidara Therapeutics	-0.16%	+6.45%	+94.42%	+179.56%	+349.47%
ERYP ERYTECH Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
FENC Adherex Technologies	+1.69%	+4.09%	+8.78%	+80.44%	+50.67%
XFOR X4 Pharmaceuticals	-5.42%	-20.10%	-55.90%	-75.08%	-91.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	4.1588 of 5 stars	3.6	2.0	0.0	4.6	3.1	1.7	0.0
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	2.3274 of 5 stars	3.6	1.0	0.0	0.0	1.8	3.3	0.0
XFOR X4 Pharmaceuticals	4.7846 of 5 stars	3.5	2.0	0.0	4.6	1.9	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXLA Axcella Health	0.00	N/A	N/A	N/A
CDTX Cidara Therapeutics	3.11	Buy	$57.14	15.34% Upside
ERYP ERYTECH Pharma	0.00	N/A	N/A	N/A
FENC Adherex Technologies	3.25	Buy	$13.00	46.98% Upside
XFOR X4 Pharmaceuticals	3.00	Buy	$72.33	4,754.59% Upside

Current Analyst Ratings Breakdown

Latest FENC, ERYP, XFOR, AXLA, and CDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$69.00
6/30/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$59.00
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$35.00 ➝ $75.00
6/24/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$50.00 ➝ $68.00
6/23/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $53.00
6/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $54.00
6/23/2025	CDTX Cidara Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$45.00
6/18/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$41.00
6/10/2025	CDTX Cidara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/20/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXLA Axcella Health	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CDTX Cidara Therapeutics	$1.27M	786.48	N/A	N/A	$14.92 per share	3.32
ERYP ERYTECH Pharma	$32.66M	3.24	N/A	N/A	$0.80 per share	3.88
FENC Adherex Technologies	$47.54M	5.14	$0.03 per share	275.27	($0.21) per share	-42.12
XFOR X4 Pharmaceuticals	$2.56M	3.37	N/A	N/A	$3.90 per share	0.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXLA Axcella Health	-$81.19M	-$19.25	N/A	∞	N/A	N/A	N/A	-259.91%	N/A
CDTX Cidara Therapeutics	-$169.83M	-$29.47	N/A	N/A	N/A	N/A	-73.04%	-54.28%	8/12/2025 (Estimated)
ERYP ERYTECH Pharma	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	-$440K	-$0.51	N/A	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
XFOR X4 Pharmaceuticals	-$37.45M	$2.14	0.70	N/A	N/A	46.54%	-181.56%	-54.36%	8/6/2025 (Estimated)

Latest FENC, ERYP, XFOR, AXLA, and CDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/1/2025	Q1 2025	XFOR X4 Pharmaceuticals	-$4.13	$0.04	+$4.17	$0.04	$7.03 million	$28.81 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXLA Axcella Health	N/A	0.80	0.80
CDTX Cidara Therapeutics	N/A	3.87	3.87
ERYP ERYTECH Pharma	0.32	3.65	3.65
FENC Adherex Technologies	N/A	5.13	4.97
XFOR X4 Pharmaceuticals	3.30	3.70	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXLA Axcella Health	65.07%
CDTX Cidara Therapeutics	35.82%
ERYP ERYTECH Pharma	1.09%
FENC Adherex Technologies	55.51%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
AXLA Axcella Health	2.20%
CDTX Cidara Therapeutics	3.89%
ERYP ERYTECH Pharma	1.94%
FENC Adherex Technologies	11.76%
XFOR X4 Pharmaceuticals	2.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXLA Axcella Health	11	2.95 million	2.88 million	Optionable
CDTX Cidara Therapeutics	90	20.16 million	19.38 million	No Data
ERYP ERYTECH Pharma	49	34.12 million	33.46 million	Not Optionable
FENC Adherex Technologies	10	27.60 million	24.35 million	Optionable
XFOR X4 Pharmaceuticals	80	5.79 million	5.65 million	Optionable

FENC, ERYP, XFOR, AXLA, and CDTX Headlines

Recent News About These Companies

X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 0.3% - Should You Sell?

July 10 at 2:23 AM | americanbankingnews.com

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

X4 Pharmaceuticals Inc News (XFOR) - Investing.com

July 2, 2025 | investing.com

XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

June 16, 2025 | globenewswire.com

X4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia Drug

June 10, 2025 | marketwatch.com

X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia

June 10, 2025 | msn.com

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

June 10, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

X4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA Congress

May 16, 2025 | nasdaq.com

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025 | globenewswire.com

X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...

May 2, 2025 | finance.yahoo.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call Transcript

May 2, 2025 | insidermonkey.com

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025 | seekingalpha.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025 | finance.yahoo.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025 | globenewswire.com

X4 Pharmaceuticals Q1 2025 Earnings Preview

April 30, 2025 | msn.com

X4 Pharmaceuticals Analyst Ratings

April 30, 2025 | benzinga.com

Earnings Preview For X4 Pharmaceuticals

April 30, 2025 | benzinga.com

Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

April 30, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC, ERYP, XFOR, AXLA, and CDTX Company Descriptions

Axcella Health NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Cidara Therapeutics NASDAQ:CDTX

$49.54 -1.34 (-2.62%)

As of 01:23 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Adherex Technologies NASDAQ:FENC

$8.85 -0.20 (-2.16%)

As of 01:21 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

X4 Pharmaceuticals NASDAQ:XFOR

$1.49 -0.08 (-5.10%)

As of 01:22 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time